CytomX Therapeutics Announces 2025 Strategic Pipeline Priorities and ProvidesCorporate Update
REGN Stock | USD 730.30 14.04 1.96% |
About 52% of Regeneron Pharmaceuticals' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Regeneron Pharmaceuticals suggests that some traders are interested. Regeneron Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Regeneron Pharmaceuticals. Many technical investors use Regeneron Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Regeneron |
- Encouraging progress supports near-term focus on lead wholly-owned program, CX-2051 . Initial Phase 1a clinical data in advanced metastatic colorectal cancer are anticipated in the first half of 2025 - - Early-stage research and platform capabilities to be concentrated on existing and potential future partnerships during 2025 - - Revised focus and associated cost and headcount reductions expected to extend cash runway into the second quarter of 2026 - - Company to pre
Read at finance.yahoo.com
Regeneron Pharmaceuticals Fundamental Analysis
We analyze Regeneron Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regeneron Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regeneron Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Short Ratio
Short Ratio Comparative Analysis
Regeneron Pharmaceuticals is currently under evaluation in short ratio category among its peers. Short Ratio is typically used by traders and speculators to identify trends in current market sentiment for a particular equity instrument. In its simple terms this ratio shows how many days it will take all current short sellers to cover their positions if the price of a stock begins to rise.
Regeneron Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regeneron Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Regeneron Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Regeneron Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Regeneron Pharmaceuticals Related Equities
RARE | Ultragenyx | 4.17 | ||||
IONS | Ionis Pharmaceuticals | 2.55 | ||||
KRYS | Krystal Biotech | 2.53 | ||||
UTHR | United Therapeutics | 1.95 | ||||
INCY | Incyte | 1.78 | ||||
BMRN | Biomarin Pharmaceutical | 1.24 | ||||
ALNY | Alnylam Pharmaceuticals | 1.20 | ||||
ARWR | Arrowhead Pharmaceuticals | 0.87 | ||||
MDGL | Madrigal Pharmaceuticals | 0.76 | ||||
APLS | Apellis Pharmaceuticals | 0.73 | ||||
BGNE | BeiGene | 0.39 | ||||
CRSP | Crispr Therapeutics | 1.20 | ||||
NVO | Novo Nordisk | 1.99 | ||||
PTCT | PTC Therapeutics | 2.56 | ||||
NTLA | Intellia Therapeutics | 2.58 | ||||
SRPT | Sarepta Therapeutics | 2.66 |
Check out Regeneron Pharmaceuticals Hype Analysis, Regeneron Pharmaceuticals Correlation and Regeneron Pharmaceuticals Performance. To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.